New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration

NDA FilingLAE002Positive

AI Analysis

Summary

Laekna announced that its New Drug Application for LAE002 (afuresertib) has been accepted by China's NMPA for treatment of patients with an unspecified indication. This represents regulatory acceptance and progression toward potential approval in China.

Outcome Details

NDA accepted by China's NMPA Center for Drug Evaluation

Importance:7/10

Sentiment:

0.70

ChinaNMPANDADrug DevelopmentRegulatory Milestone

Related Companies

$NHPAP $MDCE $CHHE

Read the original article

Published by PR Newswire Clinical Trials on August 12, 2026 12:45 AM

Read Original